These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

851 related articles for article (PubMed ID: 28284059)

  • 1. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
    Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
    Chiu SJ; Lee YJ; Hsu TS; Chen WS
    Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Plasencia C; Abad A; Martinez-Balibrea E; Taron M
    Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
    Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
    Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1.
    Rattanawong A; Payon V; Limpanasittikul W; Boonkrai C; Mutirangura A; Wonganan P
    Oncol Rep; 2018 Jan; 39(1):227-238. PubMed ID: 29138869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells.
    Hata T; Yamamoto H; Ngan CY; Koi M; Takagi A; Damdinsuren B; Yasui M; Fujie Y; Matsuzaki T; Hemmi H; Xu X; Kitani K; Seki Y; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
    Mol Cancer Ther; 2005 Oct; 4(10):1585-94. PubMed ID: 16227409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
    Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines.
    Howells LM; Mitra A; Manson MM
    Int J Cancer; 2007 Jul; 121(1):175-83. PubMed ID: 17330230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
    Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
    Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
    Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
    PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
    Wu X; Lu Y; Qin X
    J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.
    Zheng W; Luo Z; Zhang J; Min P; Li W; Xu D; Zhang Z; Xiong P; Liang H; Liu J
    Mol Med Rep; 2017 May; 15(5):2795-2801. PubMed ID: 28447739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
    Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
    Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
    Fiore D; Proto MC; Pisanti S; Picardi P; Pagano Zottola AC; Butini S; Gemma S; Casagni A; Laezza C; Vitale M; Ligresti A; Di Marzo V; Zisterer DM; Nathwani S; Williams DC; Campiani G; Gazzerro P; Bifulco M
    Cancer Biol Ther; 2016 Aug; 17(8):849-58. PubMed ID: 26392056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
    Arango D; Corner GA; Wadler S; Catalano PJ; Augenlicht LH
    Cancer Res; 2001 Jun; 61(12):4910-5. PubMed ID: 11406570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.